Mr. Ruck's mergers and acquisitions experience includes advising:

• Aon in its US$80 billion combination with Willis Towers Watson 
• The Committee of Independent Directors of T-Mobile US in its US$146 billion merger between T-Mobile US and Sprint
• Siemans Healthineers AG in its US$16.4 billion acquisition of Varian Medical Systems, Inc.
• Allergan (formerly known as Actavis/Watson) in various transactions, including: the US$40.5 billion sale of its Global Generic Pharmaceuticals Business to Teva; its US$25 billion acquisition of Forest Laboratories; its US$8.5 billion acquisition of Warner Chilcott; predecessor company Watson Pharmaceuticals in its US$5.65 billion acquisition of Actavis Group Hf in 2012, after which Watson took the target’s name; its US$1.75 billion acquisition of the Arrow Group in 2009; its US$2 billion acquisition of Andrx Corp. in 2006; its US$184 million acquisition of Makoff R&D Laboratories Inc. in 2000; and its related financings
• Mellanox in its US6.9 billion sale to NVIDIA Corporation
• Cotiviti Holdings in its US$4.9 billion acquisition by Verscend
• Guggenheim Securities and J.P. Morgan Securities as financial advisors in the US$5.4 billion acquisition of Wright Medical by Stryker
• Independent Directors of the Board of First Data Corporation in its US$22 billion acquisition by Fiserv
• Ignyta, Inc. in its US$1.7 billion acquisition by Roche
• ST Telemedia in CenturyLink's US$34 billion acquisition of Level 3 Communications, Inc. 
• Digital Realty in its US$7.6 billion acquisition of DuPont Fabros
• Raptor Pharmaceuticals in its US$800 million acquisition by Horizon Pharma plc 
• WCI Communities in its US$643 million merger with Lennar Corporation 
• Receptos in its US$7.2 billion acquisition by Celgene
• Thoratec in its US$3.4 billion acquisition by St. Jude Medical
• Amphenol Corp. in its US$1.275 billion acquisition of FCI Asia Pte Ltd.
• Apollo Global Management and TPG Capital in the formation of Caesars Growth Partners and Caesars Acquisition Corporation and the acquisition of US$2.2 billion in assets from Caesars Entertainment Corporation
• Virgin Galactic in its US$1.5 billion merger with Social Capital Hedosophia 
• Avanir Pharmaceuticals in its US$3.5 billion acquisition by Otsuka Pharmaceutical
• Starbucks Corporation in its US$913 million acquisition of Starbucks Coffee Japan, Ltd.
• The special committee of independent directors of Griffin-American Healthcare REIT II in its US$4 billion acquisition by NorthStar Realty Finance Corp.
• Spirit Realty Capital, Inc. in its US$7.4 billion merger with Cole Credit Property Trust II
• Cadence in its US$1.4 billion acquisition by a subsidiary of Mallinckrodt plc
• ArthroCare Corporation in its US$1.7 billion acquisition by Smith & Nephew
• A global public biotechnology company in several acquisitions and other transactions
• Medicis Pharmaceutical in the US$2.6 billion acquisition by Valeant Pharmaceuticals
• J.P. Morgan as financial advisor in the:
  • US$20.2 billion acquisition by Analog Devices of Maxim Integrated Products
  • pending acquisition by Cisco of ThousandEyes  
  • US$12.8 billion acquisition by UnitedHealth of Catamaran Corporation
  • US$21 billion sale of Pharmacyclics to AbbVie
  • US$3.3 billion merger of Wright Medical Group and Tornier
  • US$8.6 billion merger of MAA and Colonial Properties Trust
  • US$1.65 billion acquisition of MAKO Surgical Corp. by Stryker Corporation 
  • US$13.6 billion acquisition by Thermo Fisher of Life Technologies 
  • US$4 billion acquisition of Gambro AB by Baxter International 
  • US$2.6 billion merger of Covidien and ev3 
  • US $3.6 billion acquisition of King Pharmaceuticals by Pfizer
• Goldman, Sachs & Co. in the US$7 billion acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb
• Multimedia Games in its US$1.2 billion acquisition by Global Cash Access Holdings
• Quest Software in its US$2.4 billion acquisition by Dell
• Harrah’s Entertainment in its US$28 billion sale to affiliates of Texas Pacific Group and Apollo Management, its US$10.3 billion acquisition of Caesars Entertainment and other transactions
• Complete Production Services in its US$6.2 billion merger with Superior Energy Services
• American Medical Systems Holdings in its US$2.9 billion sale to Endo Pharmaceuticals Holdings
• ICOS Corporation in its US$2.3 billion sale to Eli Lilly
• Hydril Company and its controlling shareholders in its US$2.2 billion sale to Tenaris S.A.
• First Health Group Corp. in its US$1.9 billion acquisition of Coventry Health Care
• Adecco in its US$1.3 billion acquisition of the MPS Group
• Cougar Biotechnology in its US$1 billion sale to Johnson & Johnson
• Bank of America Merrill Lynch in the US$15.6 billion acquisition of MedImmune, Inc. by AstraZeneca , the US$11 billion acquisition by Gilead Sciences of Pharmasset, and the US$10 billion merger of Federal Express and Kinko’s
• Morgan Stanley in the US$8.1 billion merger of PacifiCare Group with UnitedHealth Group, creating one of the largest managed care and benefits companies
• Morgan Stanley in the $1.35 billion sale of UTi Worldwide to DSV
• Goldman, Sachs & Co. in the US$2.8 billion sales of Advanced Medical Optics to Abbott and the US$6.2 billion acquisition of Cytyc Corporation by Hologic